Cosmetic Procedures
Caplan Eye offers both BOTOX® Cosmetic and LATISSE®. Schedule an appointment to learn more.
Discover Proven Results
Our Cosmetic Procedures
Caplan Eye Clinic is proud to offer BOTOX® Cosmetic, which is used to improve the look of frown lines between the eyebrows, and LATISSE®, which is the first and only prescription treatment approved by the FDA for inadequate or not enough eyelashes.




Additional Information
Need to Know More About BOTOX®?
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in people 18 to 65 years of age for a short period of time (temporary).
BOTOX® Cosmetic is administered by a professional as a simple, nonsurgical treatment. It is injected directly into the muscles between the brows. It works by blocking nerve impulses to the injected muscles. This reduces muscle activity that causes moderate to severe lines to form between the brows. Individual results may vary.
Not Enough Lashes?
Find Out if LATISSE® is For You
LATISSE® is the first and only prescription treatment approved by the FDA for inadequate or insufficient eyelashes. It’s a once-a-day treatment that works gradually and effectively. Simply apply the solution topically to the base of your upper eyelashes, as instructed by your doctor. Then, results start to show in as little as 8 weeks, with full results in 16 weeks.
The science behind LATISSE®.
LATISSE® makes lash growth possible because of its active ingredient: bimatoprost. Although the precise mechanism of action is unknown, LATISSE® is believed to affect the growth phase of the eyelash hair cycle in two ways: first, it increases the length of this phase, and second, it increases the number of hairs in this growth phase.
It’s time has come.
In 2001, Allergan developed a medicated eye drop used to lower eye pressure (known as IOP or intraocular pressure) in patients with open-angle glaucoma or ocular hypertension. As a result, patients using this medication began experiencing eyelash growth as a side effect. This led Allergan, already a pioneer in eye care, dermatological and aesthetic products, to begin studying its active ingredient. After a clinical trial, LATISSE® earned its FDA approval in December 2008. And since then, approximately 1.5 million bottles of LATISSE® have been prescribed to approximately 350,000 people.
